XRP2.F SILENCE THERAP. SP.ADR/1

Healthcare Biotechnology Frankfurt Exchange
17.80 EUR
Close of Nov 12, 2026
3.40 17.80
Market cap
EUR 1.11B
P/E
-
P/B
31.96x
ROE
-141.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is XRP2.F undervalued?

Graham number

The Graham number of SILENCE THERAP. SP.ADR/1 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SILENCE THERAP. SP.ADR/1 fundamental analysis

No fundamental analysis for SILENCE THERAP. SP.ADR/1 yet.

SILENCE THERAP. SP.ADR/1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SILENCE THERAP. SP.ADR/1

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease…

Full company profile